JP2009544707A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009544707A5 JP2009544707A5 JP2009521810A JP2009521810A JP2009544707A5 JP 2009544707 A5 JP2009544707 A5 JP 2009544707A5 JP 2009521810 A JP2009521810 A JP 2009521810A JP 2009521810 A JP2009521810 A JP 2009521810A JP 2009544707 A5 JP2009544707 A5 JP 2009544707A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- protective coating
- particles
- lyophilized
- lyophilizing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002552 dosage form Substances 0.000 claims description 49
- 239000002904 solvent Substances 0.000 claims description 20
- 230000000873 masking effect Effects 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 239000011248 coating agent Substances 0.000 claims description 7
- 238000000576 coating method Methods 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- -1 microcrystalline Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000008122 artificial sweetener Substances 0.000 claims description 2
- 235000021311 artificial sweeteners Nutrition 0.000 claims description 2
- 239000003205 fragrance Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims 18
- 239000011253 protective coating Substances 0.000 claims 17
- 239000008186 active pharmaceutical agent Substances 0.000 claims 5
- 239000011230 binding agent Substances 0.000 claims 3
- 238000013270 controlled release Methods 0.000 claims 3
- 239000011159 matrix material Substances 0.000 claims 3
- 238000013268 sustained release Methods 0.000 claims 3
- 239000012730 sustained-release form Substances 0.000 claims 3
- 239000011324 bead Substances 0.000 claims 2
- 239000006172 buffering agent Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 239000008185 minitablet Substances 0.000 claims 2
- 239000008188 pellet Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical group C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 239000012615 aggregate Substances 0.000 claims 1
- 239000003086 colorant Substances 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims 1
- 229960001596 famotidine Drugs 0.000 claims 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 1
- 229960002428 fentanyl Drugs 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000013081 microcrystal Substances 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 229960001165 modafinil Drugs 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims 1
- 229960001802 phenylephrine Drugs 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000007789 sealing Methods 0.000 claims 1
- 239000002002 slurry Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000000375 suspending agent Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000004034 viscosity adjusting agent Substances 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
- 239000000080 wetting agent Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 3
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- GSHUZVSNIBLGMR-UHFFFAOYSA-N calcium;1,1-dioxo-1,2-benzothiazol-3-one Chemical compound [Ca].C1=CC=C2C(=O)NS(=O)(=O)C2=C1 GSHUZVSNIBLGMR-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06291198A EP1891938A1 (en) | 2006-07-24 | 2006-07-24 | High dose orally dissolvable/disintegrable lyophilized dosage form |
| EP06291458A EP1905429A1 (en) | 2006-09-18 | 2006-09-18 | Orally dissolvable/disintegrable lyophilized dosage forms containing protected particles |
| US11/880,503 US20080031947A1 (en) | 2006-07-24 | 2007-07-23 | Orally dissolvable/disintegrable lyophilized dosage forms containing protected |
| PCT/US2007/016690 WO2008013833A2 (en) | 2006-07-24 | 2007-07-24 | Orally dissolvable/disintegrable lyophilized dosage forms containing protected particles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009544707A JP2009544707A (ja) | 2009-12-17 |
| JP2009544707A5 true JP2009544707A5 (enExample) | 2011-08-04 |
Family
ID=39029455
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009521804A Pending JP2009544706A (ja) | 2006-07-24 | 2007-07-24 | 高用量の経口的に溶解可能／分解可能な凍結乾燥剤形 |
| JP2009521810A Pending JP2009544707A (ja) | 2006-07-24 | 2007-07-24 | 保護粒子を含有した経口的に溶解可能／分解可能な凍結乾燥剤形 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009521804A Pending JP2009544706A (ja) | 2006-07-24 | 2007-07-24 | 高用量の経口的に溶解可能／分解可能な凍結乾燥剤形 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20080031947A1 (enExample) |
| EP (2) | EP2068824A2 (enExample) |
| JP (2) | JP2009544706A (enExample) |
| CA (2) | CA2658512A1 (enExample) |
| MX (2) | MX2009000861A (enExample) |
| WO (2) | WO2008013833A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080031947A1 (en) * | 2006-07-24 | 2008-02-07 | Cima Labs Inc. | Orally dissolvable/disintegrable lyophilized dosage forms containing protected |
| EP2328558A2 (en) * | 2008-08-08 | 2011-06-08 | McNeil-PPC, Inc. | Use of sucralose as a granulating agent |
| EP2359812A1 (en) * | 2010-01-18 | 2011-08-24 | Cephalon France | Oral lyophilised compositions |
| EP2525783A1 (en) * | 2010-01-18 | 2012-11-28 | Cephalon France | Improved oral lysophilisates containing pvp/va |
| EP2645943A1 (en) | 2010-12-02 | 2013-10-09 | Agile Endosurgery, Inc. | Surgical tool |
| US9730885B2 (en) | 2012-07-12 | 2017-08-15 | Mallinckrodt Llc | Extended release, abuse deterrent pharmaceutical compositions |
| US11058642B2 (en) * | 2013-04-22 | 2021-07-13 | Tower Laboratories Ltd | Tablets with improved friability |
| US9650338B1 (en) | 2016-07-29 | 2017-05-16 | VDM Biochemicals, Inc. | Opioid antagonist compounds and methods of making and using |
| WO2018191794A1 (en) | 2017-04-20 | 2018-10-25 | Zeenar Enterprises Pty Ltd | Liquid crystalline dosage form for administering a statin |
| AU2018255718A1 (en) | 2017-04-20 | 2019-12-05 | Zeenar Enterprises Pty Ltd | Fast disintegrating tablet |
| CN111432804A (zh) * | 2017-11-27 | 2020-07-17 | 帝斯曼知识产权资产管理有限公司 | 冻干的多微粒固体剂型 |
| CA3157405A1 (en) | 2019-11-18 | 2021-05-27 | Donald D. EVANS II | Lyophilized cake in straight-walled vial |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH558659A (fr) * | 1969-11-26 | 1975-02-14 | Orsymonde | Procede pour la preparation d'une composition lyophilisee a usage hygienique. |
| GB1447988A (en) * | 1973-04-03 | 1976-09-02 | Orsymonde | Pharmaceutical compositions |
| FR2539626B2 (fr) * | 1983-01-25 | 1985-06-21 | Lafon Labor | Nouveau procede de preparation de formes galeniques utiles notamment en therapeutique, dietetique, cosmetique et diagnostic, et formes obtenues selon ce procede |
| FR2561916B1 (fr) * | 1984-03-30 | 1987-12-11 | Lafon Labor | Forme galenique pour administration orale et son procede de preparation par lyophilisation d'une emission huile dans eau |
| GB8724763D0 (en) * | 1987-10-22 | 1987-11-25 | Aps Research Ltd | Sustained-release formulations |
| DE3824399A1 (de) * | 1988-07-19 | 1990-01-25 | Ford Werke Ag | Regelbares ringreibgetriebe |
| FR2634376B1 (fr) * | 1988-07-21 | 1992-04-17 | Farmalyoc | Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation |
| US5178878A (en) * | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
| US5223264A (en) * | 1989-10-02 | 1993-06-29 | Cima Labs, Inc. | Pediatric effervescent dosage form |
| US5558880A (en) * | 1989-12-22 | 1996-09-24 | Janssen Pharmaceutica Inc. | Pharmaceutical and other dosage forms |
| US5188825A (en) * | 1989-12-28 | 1993-02-23 | Iles Martin C | Freeze-dried dosage forms and methods for preparing the same |
| US5843347A (en) * | 1993-03-23 | 1998-12-01 | Laboratoire L. Lafon | Extrusion and freeze-drying method for preparing particles containing an active ingredient |
| CA2128821A1 (en) * | 1993-07-27 | 1995-01-28 | Dilip J. Gole | Freeze-dried pharmaceutical dosage form and process for separation thereof |
| DK9500167U3 (da) * | 1995-04-27 | 1996-01-12 | Brdr Christensens Haner A S | Afspærringsindretning af "double-block-and-bleed"-typen |
| US5599846A (en) * | 1996-06-28 | 1997-02-04 | Jame Fine Chemicals, Inc. | Phenylephrine tannate compositions |
| US6024981A (en) * | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
| US5976577A (en) * | 1997-07-11 | 1999-11-02 | Rp Scherer Corporation | Process for preparing fast dispersing solid oral dosage form |
| US6479496B1 (en) * | 1998-09-10 | 2002-11-12 | Cv Therapeutics, Inc. | Methods for treating angina with ranolazine |
| US6740341B1 (en) * | 1998-11-25 | 2004-05-25 | Cima Labs Inc. | Taste masking rapid release coating system |
| AU2023401A (en) * | 1999-12-01 | 2001-06-12 | Natco Pharma Limited | A rapid acting freeze dired oral pharmaceutical composition for treating migraine |
| US6754511B1 (en) * | 2000-02-04 | 2004-06-22 | Harris Corporation | Linear signal separation using polarization diversity |
| US6316029B1 (en) * | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
| JP2003055197A (ja) * | 2001-06-07 | 2003-02-26 | Tanabe Seiyaku Co Ltd | 機能性粒子含有口腔内速崩壊性製剤 |
| CA2449731A1 (en) * | 2001-06-07 | 2002-12-19 | Tanabe Seiyaku Co., Ltd. | Functional grain-containing preparations quickly disintegrated in the oral cavity |
| US20030190343A1 (en) * | 2002-03-05 | 2003-10-09 | Pfizer Inc. | Palatable pharmaceutical compositions for companion animals |
| EP1496867A1 (en) * | 2002-04-08 | 2005-01-19 | Lavipharm Laboratories, Inc. | Drug-complex microparticles and methods of making/using same |
| CA2497176A1 (en) * | 2002-09-04 | 2004-03-18 | Ranbaxy Laboratories Limited | Taste masked dosage forms and processes for their preparation |
| US7994214B2 (en) * | 2003-08-29 | 2011-08-09 | Lifecycle Pharma A/S | Solid dispersions comprising tacrolimus |
| US20050123596A1 (en) * | 2003-09-23 | 2005-06-09 | Kohane Daniel S. | pH-triggered microparticles |
| US7294347B2 (en) * | 2004-06-21 | 2007-11-13 | Council Of Scientific And Industrial Research | Coating compositions for bitterness inhibition |
| US20060024370A1 (en) * | 2004-07-29 | 2006-02-02 | Cephalon France | Modafinil oral lyophilizate |
| US8193211B2 (en) * | 2004-09-30 | 2012-06-05 | Supernus Pharmaceuticals, Inc. | Controlled release compositions of gamma-hydroxybutyrate |
| US20080031947A1 (en) * | 2006-07-24 | 2008-02-07 | Cima Labs Inc. | Orally dissolvable/disintegrable lyophilized dosage forms containing protected |
-
2007
- 2007-07-23 US US11/880,503 patent/US20080031947A1/en not_active Abandoned
- 2007-07-23 US US11/880,531 patent/US20080031949A1/en not_active Abandoned
- 2007-07-24 WO PCT/US2007/016690 patent/WO2008013833A2/en not_active Ceased
- 2007-07-24 WO PCT/US2007/016638 patent/WO2008013808A2/en not_active Ceased
- 2007-07-24 MX MX2009000861A patent/MX2009000861A/es active IP Right Grant
- 2007-07-24 CA CA002658512A patent/CA2658512A1/en not_active Abandoned
- 2007-07-24 EP EP07810726A patent/EP2068824A2/en not_active Withdrawn
- 2007-07-24 MX MX2009000849A patent/MX2009000849A/es active IP Right Grant
- 2007-07-24 EP EP07836223A patent/EP2068826A2/en not_active Withdrawn
- 2007-07-24 JP JP2009521804A patent/JP2009544706A/ja active Pending
- 2007-07-24 CA CA002658109A patent/CA2658109A1/en not_active Abandoned
- 2007-07-24 JP JP2009521810A patent/JP2009544707A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Streubel et al. | Drug delivery to the upper small intestine window using gastroretentive technologies | |
| ES2319266T3 (es) | Comprimidos efervescentes bucodispersables. | |
| KR102017009B1 (ko) | 설하 아포모르핀 | |
| JP2009544706A5 (enExample) | ||
| RU2527766C2 (ru) | Таблетки и гранулированные порошки, содержащие 6-фтор-3-гидрокси-2-пиразинкарбоксамид | |
| IL147212A (en) | Process to create coated kernels with camouflaged flavor | |
| ES2543427T3 (es) | Forma farmacéutica oral de deferasirox | |
| ES2364538T3 (es) | Combinación farmacéutica de alisquireno y valsartán. | |
| MX2011007399A (es) | Suspension farmaceutica de liberacion doble. | |
| BR112014026292B1 (pt) | Comprimido oralmente desintegrável, e, processo para a produção de um comprimido oralmente desintegrável | |
| PT1789021E (pt) | Formulação de comprimidos de libertação prolongada contendo pramipexole ou um seu sal farmaceuticamente aceitável | |
| KR20120110167A (ko) | 특이적으로 변형된 방출 프로필이 제공된 항-오용 고체 경구 투여 제형 | |
| ES2623176T3 (es) | Composición farmacéutica de memantina | |
| ES2829644T3 (es) | Composición farmacéutica oral de sabor enmascarado | |
| JP6768070B2 (ja) | 粘膜付着性医薬組成物及びその製造方法 | |
| WO2004066924A2 (en) | Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid | |
| TW200902089A (en) | Solid pharmaceutical composition | |
| WO2006133349A2 (en) | Orally disintegrable sleep aid formulations | |
| BRPI0407116B1 (pt) | Partícula revestida baseada em princípio ativo, composição farmacêutica ou cosmética, e, método para produção de partícula revestida baseada em princípio ativo | |
| ES2729191T3 (es) | Composición farmacéutica que contiene macitentan cristalino | |
| WO2008013808A2 (en) | High dose orally dissolvable/disintegrable lyophilized dosage form | |
| Sharma et al. | Oral Disintegrating tablets–an updated patent perspective | |
| Suradkar et al. | Overview on trends in development of gastroretentive drug delivery system | |
| Setia et al. | Gastro-retentive floating beads a new trend of drug delivery system | |
| Kumar et al. | An Updated Overview of Gastro-retentive Floating Drug Delivery Systems: Formulation Strategies and Application. |